Contact us for information and resources about ZETIA
We will be pleased to assist you Monday through Thursday from 8 AM to 8 PM ET, Friday from 8 AM to 6 PM ET. (with the exception of holidays and certain dates around holidays).
Now, there is a fast and easy way to obtain:
- • Samples of ZETIA
- • Access to relevant clinical articles
- • Product information from Merck
- • Educational materials for your patients
- • Answers to clinical questions about ZETIA
If you would prefer to use only the phone, you can speak directly with a Merck representative by calling 800-537-8172.
Request more information
Sign up now and be the first to know about Web site updates, including new clinical studies and interactive tools to support your patients and your practice. Simply enter the following information and click the I AGREE button below.
- • The effect of ZETIA on cardiovascular morbidity and mortality has not been determined.
- • ZETIA, administered alone or in combination with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated TOTAL-C, LDL-C, Apo B, and non–HDL-C in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia when diet alone is not enough.
- SELECTED CAUTIONARY INFORMATION
- • Because renal impairment is a risk factor for statin-associated myopathy, doses of simvastatin exceeding 20 mg should be used with caution and close monitoring when administered concomitantly with ZETIA in patients with moderate to severe renal impairment (eGFR <60 mL/min/1.73 m2).
- • ZETIA is not recommended in patients with moderate to severe hepatic impairment.
- • The coadministration of ZETIA with fibrates other than fenofibrate is not recommended until use in patients is adequately studied.
- • Exercise caution when using ZETIA and cyclosporine concomitantly because exposure to both drugs is increased. Cyclosporine concentrations should be monitored in these patients.
- • ZETIA should be used in pregnant or nursing women only if the benefit outweighs the risk.
- • In clinical trials, regardless of causality assessment, the most frequent side effects for ZETIA coadministered with a statin vs statin alone included nasopharyngitis (3.7% vs 3.3%), myalgia (3.2% vs 2.7%), upper respiratory tract infection (2.9% vs 2.8%), arthralgia (2.6% vs 2.4%), and diarrhea (2.5% vs 2.2%); for ZETIA administered alone vs placebo: upper respiratory tract infection (4.3% vs 2.5%), diarrhea (4.1% vs 3.7%), arthralgia (3.0% vs 2.2%), sinusitis (2.8% vs 2.2%), pain in extremity (2.7% vs 2.5%), and fatigue (2.4% vs 1.5%).